Small Business Innovative Research Program (SBIR) Opportunities to Access the Treatment Units for Research on Neurocognition and Schizophrenia (TURNS)

Notice Number: NOT-MH-07-116

Key Dates
Release Date: June 14, 2007

Issued by
National Institute of Mental Health (NIMH) (http://www.nimh.nih.gov)
National Institutes of Health (NIH) (http://www.nih.gov)

The purpose of this Notice is to inform the small business research community of the availability to use the Treatment Units for Research on Neurocognition and Schizophrenia (TURNS), which comprises a network of academic centers that will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia.  The TURNS is one component of a multipronged NIMH effort to stimulate academic and industry-sponsored research focused on cognitive deficits in schizophrenia.  Small businesses developing compounds as potential treatments for the cognitive effects of schizophrenia have the opportunity to apply to TURNS to submit their compounds into the network for some preclinical efficacy testing and for clinical testing. The compound review process typically occurs within two weeks of submission.  For more information on TURNS or for TURNS application information, please see:  http://www.turns.ucla.edu/

If the small business’s proposal has been accepted into the program, the small business can then apply to the SBIR program for funds to cover the costs of the proposal, through the NIMH Funding Opportunity Announcement (FOA) entitled, “Pharmacologic Agents and Drugs for Mental Disorders (SBIR [R43/R44])”,  http://grants.nih.gov/grants/guide/pa-files/PA-06-027.html. This FOA allows Phase I budgets of $250,000 total costs per year for up to two years, and Phase II budgets of up to $450,000 per year for up to three years.  If the small business is awarded a Phase II SBIR grant, they then can apply for a Phase II competing renewal award to help further the development and testing of the compound, through the NIMH FOA entitled, “Competing Renewal Awards of SBIR Phase II Grants for Pharmacologic Agents and Drugs for Mental Disorders (SBIR R43/R44), http://grants.nih.gov/grants/guide/pa-files/PA-06-079.html.  This competing renewal FOA allows up to $800,000 in total costs per year for up to three additional years of funding.  Together, the total funding available through these two FOAs, including the Phase I, Phase II, and the competing renewal of the Phase II grant allows up to $4.25M over eight years.  Applicants are encouraged to contact Dr. Margaret Grabb prior to submitting an SBIR application for this program.

Additional information

For more information on TURNS or for TURNS application information, please see:  http://www.turns.ucla.edu/.
For more information on the NIH SBIR program, please see: http://grants.nih.gov/grants/funding/sbir.htm.

Inquiries

Inquiries regarding this Notice should be directed to:

Margaret Grabb, Ph.D.
National Institute of Mental Health
6001 Executive Boulevard, Room 7201, MSC 9645
Bethesda, MD 20892-9645
Rockville, MD 20852 (for express or courier service)
Telephone: (301) 443-3563
Email: mgrabb@mail.nih.gov


Weekly TOC for this Announcement
NIH Funding Opportunities and Notices


Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS)
  USA.gov - Government Made Easy


Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.